Experience

Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million aggregate principal amount of 0.25% convertible senior notes due…

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million. Atreca is a…

Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…

Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …

Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…